12 completed, 5 recruiting, 3 unknown, 1 enrolling by invitation. 9 Phase 2, 9 Phase 3, 2 Not applicable, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Recruiting 2, Enrolling by invitation 1 |
| Phase 3 | 9 | Completed 6, Recruiting 3 |
| Not applicable | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Hypogammaglobulinemia: new trials by email Literature Review of Hypogammaglobulinemia trials Research Report on Hypogammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections Panzyga, 10% Intravenous Solution, Placebo - Hypogammaglobulinemia, Autoimmune Conditions | Phase 3 | Recruiting | Octapharma | 360 | 2026-06-10 | 2026-10-28 |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia IgPro20 - Multiple Myeloma, Hypogammaglobulinemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2025-05-08 | 2026-10-05 |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma Xembify, Placebo - Hypogammaglobulinemia, Bacterial Infections | Phase 3 | Recruiting | Grifols Therapeutics LLC | 386 | 2022-12-26 | 2026-09-30 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins - Haematological Malignancy, Hypogammaglobulinemia | Phase 2 / Phase 3 | Recruiting | Monash University | 300 | 2022-11-30 | 2024-04-19 |
| Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? Laboratory test - Hypogammaglobulinemia, Multiple Sclerosis | Recruiting | Insel Gruppe AG, University Hospital Bern | 106 | 2022-07-01 | 2026-05-01 | |
| Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Completed | Octapharma | 247 | 2020-10-05 | 2026-06-04 |
| Immunodeficiency in MS No Interventions - Multiple Sclerosis, Hypogammaglobulinemia | Unknown | Advanced Neurosciences Institute | 1500 | 2020-06-29 | 2020-06-25 | |
| Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis Serum immunoglobulin titer - Multiple Sclerosis, Hypogammaglobulinemia | Unknown | Mazandaran University of Medical Sciences | 170 | 2020-02-28 | 2020-07-10 | |
| Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients subcutaneous immunoglobulin - Hypogammaglobulinemia | Not applicable | Completed | University Health Network, Toronto | 20 | 2018-02-01 | 2019-05-09 |
| Personalized Immunotherapeutic for Antibiotic-resistant Infection anti-mycoplasma hominis antibodies - Infection, Immune Deficiency | Early Phase 1 | Completed | Brigham and Women's Hospital | 1 | 2016-04-12 | 2020-01-18 |
| Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Plerixafor, G-CSF - Myelokathexis, Infections | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2014-10-14 | 2026-06-26 |
| Post-bypass Prophylactic IVIG in Infants and Neonates IVIG, Placebo - Hypogammaglobulinemia, Congenital Heart Disease | Not applicable | Completed | University of Alabama at Birmingham | 50 | 2014-05-01 | 2017-04-13 |
| Investigation of Immune Disorders and Deficiencies Primary Immune Deficiencies, Autoimmune Diseases | Unknown | O & O Alpan LLC | 343 | 2012-12-01 | 2017-04-04 | |
| Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Kedrion IVIG 10% - Primary Immunodeficiency, Agammaglobulinemia | Phase 3 | Completed | Kedrion S.p.A. | 45 | 2012-11-12 | 2021-02-16 |
| Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Lenalidomide, Ofatumumab - Chronic Lymphocytic Leukemia, Fatigue | Phase 2 | Completed | M.D. Anderson Cancer Center | 36 | 2010-01-19 | 2019-05-07 |
| Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Gammaplex (Intravenous immunoglobulin) - Primary Immunodeficiency, Common Variable Hypogammaglobulinemia | Phase 3 | Completed | Bio Products Laboratory | 50 | 2006-01-01 | 2013-01-24 |
| Intravenous Immunoglobulin (IVIG) in Lung Transplantation IVIG, Placebo - Hypogammaglobulinemia, Lung Transplantation | Phase 2 | Completed | Columbia University | 11 | 2005-06-01 | 2019-03-05 |
| Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution, Gammagard S/D (Solvent/Detergent) - Primary Immunodeficiency Diseases (PID), Agammaglobulinemia | Phase 2 | Completed | Baxalta now part of Shire | 24 | 2002-06-13 | 2021-08-24 |
| Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients IVIG-L - Hypogammaglobulinemia | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 15 | 2001-05-01 | 2007-04-19 |
Showing 20 of 21. Sign in to see all of them.
Agammaglobulinemia (21) · Immunologic Deficiency Syndromes (4) · Infections (4) · Primary Immunodeficiency Diseases (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Multiple Sclerosis (3) · Bacterial Infections (2) · Common Variable Immunodeficiency (2) · Fatigue (2) · Warts (2) · Arthritis, Infectious (1) · Autoimmune Diseases (1) · Fever (1) · Heart Defects, Congenital (1) · Hematologic Neoplasms (1)
Blood Protein Disorders (21) · Hematologic Diseases (21) · Hemic and Lymphatic Diseases (21) · Immune System Diseases (21) · Lymphatic Diseases (21) · Lymphoproliferative Disorders (21) · Immunologic Deficiency Syndromes (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Immunoproliferative Disorders (5) · Neoplasms by Histologic Type (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4) · Genetic Diseases, Inborn (4) · Neoplasms (4) · Pathologic Processes (4)
gamma-Globulins (4) · Immunoglobulins, Intravenous (3) · Filgrastim (2) · Panzyga (2) · Saline Solution (2) · plerixafor (2) · Amoxicillin (1) · Busulfan (1) · Ciprofloxacin (1) · Clavulanic Acid (1) · Clinical Laboratory Techniques (1) · Detergents (1) · Fibroblast Growth Factor 7 (1) · Granulocyte Colony-Stimulating Factor (1) · Hizentra (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Octapharma (2) · Advanced Neurosciences Institute (1) · Baxalta now part of Shire (1) · Bio Products Laboratory (1) · Brigham and Women's Hospital (1) · Columbia University (1) · Grifols Therapeutics LLC (1) · Insel Gruppe AG, University Hospital Bern (1) · Kedrion S.p.A. (1) · M.D. Anderson Cancer Center (1) · Mazandaran University of Medical Sciences (1) · Memorial Sloan Kettering Cancer Center (1) · Monash University (1) · O & O Alpan LLC (1)
United States (15) · Poland (3) · Bulgaria (2) · Canada (2) · Czechia (2) · Greece (2) · Hungary (2) · Australia (1) · Bosnia and Herzegovina (1) · Croatia (1) · Denmark (1) · Finland (1) · Germany (1) · Iran (1) · Israel (1)
Alessandra Ferrajoli (1) · David H McDermott, M.D. (1) · Duane R. Wesemann, MD, PhD (1) · Fotios V. Michelis, MD, PhD (1) · Jeff T Chapman, MD (1) · Jeffrey Alten, MD (1) · Lara Diem, MD (1) · Melvin Berger, MD (1) · Mirella Calcinai, MD (1) · Oral Alpan, MD (1) · Prof Erica Wood (1) · Prof Zoe McQuilten (1) · Samuel F Hunter, MD, PhD (1) · Selim M Arcasoy, M.D. (1)
PMID 25090414, PMID 29272362, PMID 29358183, PMID 33684377, PMID 36818468, PMID 37561579, PMID 42606118
P30CA016672 (1)